

Paul Smith  
University College London  
Lymphoma Trials Office,  
222 Euston Road  
London  
NW1 2DA

CTA number: 20363/0204/001  
EudraCT number: 2004-002197-34

24 August 2006

Dear Mr Smith,

**THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 1031**


**Product: Rituximab**  
**Protocol number: 04/Q1104/27**

**NOTICE OF ACCEPTANCE OF AMENDMENT (Version 2)**

I am writing to confirm that the Licensing Authority, in accordance with regulation 24(5)(b) accepts the proposed amendments contained in your notice of amendments received on 1 August 2006 relating to the Clinical Trial Authorisation identified by the above CTA number, subject to the relevant ethics committee giving a favourable opinion in accordance with regulation 24(9).

This trial may therefore proceed accordingly.

Yours sincerely



**Dr Carolyn Greenwood**  
Medical Assessor  
Clinical Trials Unit

Direct Line: 020 7084 2327, Facsimile: 020 7084 2443, Room: 12-242

RECEIVED 29 AUG 2006